The pharmacodynamics of morphine-6-glucuronide (M-6-G) i.v. were assessed in 12 healthy male volunteers in an open study. After a single bolus dose of M-6-G 5 mg i.v., we measured antinociceptive effects, using electrical and cold pain tests, and plasma concentrations of M-6-G, morphine-3-glucuronide (M-3-G) and morphine. Pain intensities during electrical stimulation (at 30, 60 and 90 min after injection) and ice water immersion (at 60 min) decreased significantly (PϽ0.005) compared with baseline. Mean plasma peak concentrations of M-6-G were 139.3 (SD 38.9) ng ml -1 , measured at 15 min. Our data demonstrate that M-6-G has significant analgesic activity.
The major metabolites of morphine are morphine-6-glucu-every 15 min for the first 2 h and then hourly until the end ronide (M-6-G) and morphine-3-glucuronide (M-3-G). 1 of the study (5 h). One subject received M-6-G 10 mg and M-6-G has a 100-fold higher affinity for µ opioid receptors another subject 20 mg orally. compared with morphine when given intrathecally, and Subjects were instructed in detail concerning the pain shows analgesic activity. 2 Systemic M-6-G has been shown tests and a practice run was performed before actual data to be approximately equipotent to morphine with respect collection. During testing, subjects were in a quiet, warm to analgesic activity but with fewer side effects. 2 However, room, in a comfortable sitting position. Two standardized a recent study failed to demonstrate analgesic activity of tests were performed. In the ice bucket pain test, the M-6-G i.v. in healthy volunteers. 3 In this study, we have non-dominant hand was immersed in an ice water bath examined the analgesic activity of M-6-G i.v. in human maintained at a constant temperature of 4°C and pain volunteers using opioid sensitive pain tests, and related this intensity was noted after 170 s on a 100-mm visual analogue to plasma concentrations. scale (VAS; 0ϭno pain, 100ϭunbearable pain). In the electrical pain stimulation test, the pain tolerance threshold
Methods and results
was determined by increasing the current applied with an electrical nerve stimulator (100 Hz tetanic stimulation, After obtaining approved from the Ethics Committee of the Digistim, Biometer A/S, Copenhagen, Denmark) to the University of Berne and written informed consent, we thenar eminence of the dominant hand by 0.1 mA s -1 until studied 12 healthy male volunteers (aged 21-46 yr, weight the pain sensation became 'intolerable'. Prior reduction of 53-80 kg) in an open study. Before injection of M-6-G, a skin resistance was ensured by degreasing and scrubbing baseline blood sample was obtained from the right antecuthe skin with emery paper. The tolerance threshold current bital vein and control pain tests conducted. After a light was applied on two occasions for 30 s and pain scores were standardized meal, M-6-G 5 mg (Lipomed, Allschwil, noted on a VAS. Both pain tests were performed 10 min Switzerland; Ͼ98.5% HPLC purity), dissolved shortly before and 30, 60, 90, 120, 180 and 300 min after injection before use in sterile isotonic saline 5 ml, was injected as an i.v. bolus dose over 1 min. Blood samples were obtained of M-6-G. Side effects were noted.
Comment
We have demonstrated that M-6-G has analgesic activity in human volunteers after i.v. application when appropriate and sensitive pain tests are used, corroborating earlier studies in patients and healthy subjects. 2 In contrast, a recent placebo-and morphine-controlled study 3 reported a lack of analgesic activity after constant infusion of M-6-G, although steady-state M-6-G plasma concentrations (70-175 ng ml -1 ) were similar to those in our study (90-228 ng ml -1 ). However, the study of Loetsch and colleagues 3 must be interpreted with caution because of the very high incidence of opioid effects and use of naloxone and antiemetics almost exclusively in the morphine group. The resultant unblinding may have prejudiced volunteer reactions and it is possible that the rescue medication itself had effects on nociception. Moreover, the pain-evoked cerebral late potentials used in their study are recognized to be multifactorial in origin and cannot be assumed to measure sensory discriminative responses to pain, but rather reflect emotional-motivational aspects of pain. 5 Late potentials of this type are particularly sensitive to non-analgesic crucial, as phasic, mainly A-δ fibre activating stimuli, as used by Loetsch and colleagues, have been shown to be insensitive for this purpose. 6 The tonic and suprathreshold pain tolerance tests in our study were chosen to ensure activation of C-fibres sensitive to opioid effects. Although Statistical analysis was performed using analysis of qualitative responses to electrical and cold pain stimulation variance (ANOVA) and post hoc Tukey's honest significance were similar, the former is a multimodal stimulus and the test. PϽ0.05 was considered significant. latter probably monomodal. Clinical studies with patients are Concentrations of M-6-G, M-3-G and morphine in plasma now necessary to further evaluate the therapeutic potential of were assayed by high-pressure liquid chromatography with M-6-G. diode-array detection (HPLC-DAD). 4 All 12 volunteers completed the pain tests. There were no serious or objective side effects. Subjective effects were sensations of heaviness, warmth and faster pulse (12 of 12 Acknowledgements bucket and electrical pain tests was highly significant (PϽ0.0001) (Fig. 1A) . Pain intensities during electrical stimulation were significantly lower than baseline at 30, 60
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With the ice bucket test, pain intensity at 60 min was and its 3-and 6-glucuronide metabolites in humans and animals, significantly lower than that at baseline (Pϭ0.004). At other and the importance of the metabolites to the pharmacological times differences were not significant. In two subjects 
